235 related articles for article (PubMed ID: 36569935)
1. Exploitation of tumor antigens and construction of immune subtype classifier for mRNA vaccine development in bladder cancer.
Zhang X; Zhang Y; Zhao L; Wang J; Li J; Wang X; Zhang M; Hu X
Front Immunol; 2022; 13():1014638. PubMed ID: 36569935
[TBL] [Abstract][Full Text] [Related]
2. Identification of tumor antigens and immune landscapes for bladder urothelial carcinoma mRNA vaccine.
Sun Z; Jing C; Zhan H; Guo X; Suo N; Kong F; Tao W; Xiao C; Hu D; Wang H; Jiang S
Front Immunol; 2023; 14():1097472. PubMed ID: 36761744
[TBL] [Abstract][Full Text] [Related]
3. Identification of three tumor antigens and immune subtypes for mRNA vaccine development in diffuse glioma.
Zhou Q; Yan X; Zhu H; Xin Z; Zhao J; Shen W; Yin W; Guo Y; Xu H; Zhao M; Liu W; Jiang X; Ren C
Theranostics; 2021; 11(20):9775-9790. PubMed ID: 34815785
[No Abstract] [Full Text] [Related]
4. Identification of Novel Tumor Antigens and the Immune Landscapes of Bladder Cancer Patients for mRNA Vaccine Development.
Wang G; Gao Y; Chen Y; Wang K; Zhang S; Li G
Front Oncol; 2022; 12():921711. PubMed ID: 35814377
[TBL] [Abstract][Full Text] [Related]
5. A novel metabolic subtype with S100A7 high expression represents poor prognosis and immuno-suppressive tumor microenvironment in bladder cancer.
Cai Y; Cheng Y; Wang Z; Li L; Qian Z; Xia W; Yu W
BMC Cancer; 2023 Aug; 23(1):725. PubMed ID: 37543645
[TBL] [Abstract][Full Text] [Related]
6. Robust pyroptosis risk score guides the treatment options and predicts the prognosis of bladder carcinoma.
Deng D; Liu F; Liu Z; Wu Z; He Y; Zhang C; Zu X; Ou Z; Wang Y
Front Immunol; 2022; 13():965469. PubMed ID: 36090967
[TBL] [Abstract][Full Text] [Related]
7. Deciphering the immunological and prognostic features of bladder cancer through platinum-resistance-related genes analysis and identifying potential therapeutic target P4HB.
Xiong S; Li S; Zeng J; Nie J; Liu T; Liu X; Chen L; Fu B; Deng J; Xu S
Front Immunol; 2023; 14():1253586. PubMed ID: 37790935
[TBL] [Abstract][Full Text] [Related]
8. Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer.
Hu J; Yu A; Othmane B; Qiu D; Li H; Li C; Liu P; Ren W; Chen M; Gong G; Guo X; Zhang H; Chen J; Zu X
Theranostics; 2021; 11(7):3089-3108. PubMed ID: 33537076
[No Abstract] [Full Text] [Related]
9. Prognostic value of COL10A1 and its correlation with tumor-infiltrating immune cells in urothelial bladder cancer: A comprehensive study based on bioinformatics and clinical analysis validation.
Wang X; Bai Y; Zhang F; Li D; Chen K; Wu R; Tang Y; Wei X; Han P
Front Immunol; 2023; 14():955949. PubMed ID: 37006317
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of MTHFD2 represents an inflamed tumor microenvironment and precisely predicts the molecular subtype and immunotherapy response of bladder cancer.
Shi X; Peng X; Chen Y; Shi Z; Yue C; Zuo L; Zhang L; Gao S
Front Immunol; 2023; 14():1326509. PubMed ID: 38130721
[TBL] [Abstract][Full Text] [Related]
11. The Immune Cell Infiltration Patterns and Characterization Score in Bladder Cancer to Identify Prognosis.
Zhang Y; Wang Y; Wang J; Zhang K
Front Genet; 2022; 13():852708. PubMed ID: 35801082
[No Abstract] [Full Text] [Related]
12. Recognition of Tumor-Associated Antigens and Immune Subtypes in Glioma for mRNA Vaccine Development.
Ma S; Ba Y; Ji H; Wang F; Du J; Hu S
Front Immunol; 2021; 12():738435. PubMed ID: 34603319
[TBL] [Abstract][Full Text] [Related]
13. Identification of tumor antigens and immune subtypes of cholangiocarcinoma for mRNA vaccine development.
Huang X; Tang T; Zhang G; Liang T
Mol Cancer; 2021 Mar; 20(1):50. PubMed ID: 33685460
[TBL] [Abstract][Full Text] [Related]
14. Screening of Tumor Antigens and Construction of Immune Subtypes for mRNA Vaccine Development in Head and Neck Squamous Cell Carcinoma.
Li HX; Liu TR; Tu ZX; Xie CB; Wen WP; Sun W
Biomolecules; 2022 Dec; 13(1):. PubMed ID: 36671475
[TBL] [Abstract][Full Text] [Related]
15. FGFR3 mutation characterization identifies prognostic and immune-related gene signatures in bladder cancer.
Xu PH; Chen S; Wang Y; Jin S; Wang J; Ye D; Zhu X; Shen Y
Comput Biol Med; 2023 Aug; 162():106976. PubMed ID: 37301098
[TBL] [Abstract][Full Text] [Related]
16. Identification of NTRK3 as a potential prognostic biomarker associated with tumor mutation burden and immune infiltration in bladder cancer.
Zhang Z; Yu Y; Zhang P; Ma G; Zhang M; Liang Y; Jiao W; Niu H
BMC Cancer; 2021 Apr; 21(1):458. PubMed ID: 33894748
[TBL] [Abstract][Full Text] [Related]
17. PRR11 is a prognostic biomarker and correlates with immune infiltrates in bladder urothelial carcinoma.
Ni W; Yi L; Dong X; Cao M; Zheng J; Wei Q; Yuan C
Sci Rep; 2023 Feb; 13(1):2051. PubMed ID: 36739300
[TBL] [Abstract][Full Text] [Related]
18. Identification of tumor antigens and immune subtypes of acute myeloid leukemia for mRNA vaccine development.
Wang F
Clin Transl Oncol; 2023 Jul; 25(7):2204-2223. PubMed ID: 36781600
[TBL] [Abstract][Full Text] [Related]
19. An effective N6-methyladenosine-related long non-coding RNA prognostic signature for predicting the prognosis of patients with bladder cancer.
Ma T; Wang X; Meng L; Liu X; Wang J; Zhang W; Tian Z; Zhang Y
BMC Cancer; 2021 Nov; 21(1):1256. PubMed ID: 34802433
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive Investigation of Genes Associated with Cell Cycle Pathways for Prognosis and Immunotherapy in Bladder Urothelial Carcinoma.
Mi Y; Wang X
J Environ Pathol Toxicol Oncol; 2022; 41(3):1-12. PubMed ID: 35993952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
